2019
Reduced patency in left-sided arteriovenous grafts in a porcine model
Liu S, Wang T, Wang J, Isaji T, Ono S, Fereydooni A, Taniguchi R, Matsubara Y, Niklason LE, Dardik A. Reduced patency in left-sided arteriovenous grafts in a porcine model. Journal Of Vascular Surgery 2019, 72: 305-317.e6. PMID: 31699515, PMCID: PMC7196525, DOI: 10.1016/j.jvs.2019.06.221.Peer-Reviewed Original ResearchConceptsInternal jugular veinBlood flow velocityArteriovenous prosthetic graftsProsthetic graftsPolytetrafluoroethylene graftsArteriovenous graftsPreclinical modelsCarotid arteryJugular veinHemodialysis vascular access failurePorcine arteriovenous graft modelSimilar blood flow velocitiesActin-positive smooth muscle cellsPhosphorylated endothelial nitric oxide synthasePorcine modelEndothelial nitric oxide synthaseLeft-sided graftsLeft-sided veinsProsthetic graft patencyRight-sided graftsRight-sided veinsCentral vein catheterVascular access failureShort-term patencyArteriovenous polytetrafluoroethylene graftsEndovascular Revascularization Incorporating Infrapopliteal Coronary Drug-Eluting Stents Improves Clinical Outcomes in Patients with Critical Limb Ischemia and Tissue Loss
Huntress LA, Fereydooni A, Dardik A, Nassiri N. Endovascular Revascularization Incorporating Infrapopliteal Coronary Drug-Eluting Stents Improves Clinical Outcomes in Patients with Critical Limb Ischemia and Tissue Loss. Annals Of Vascular Surgery 2019, 63: 234-240. PMID: 31563654, DOI: 10.1016/j.avsg.2019.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalConstriction, PathologicCritical IllnessDrug-Eluting StentsEndovascular ProceduresFemaleHumansIschemiaMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProgression-Free SurvivalProsthesis DesignRetrospective StudiesRisk FactorsTime FactorsUnited StatesVascular PatencyWound HealingConceptsCritical limb ischemiaCoronary drug-eluting stentsDrug-eluting stentsWIfI scoreMajor amputationEndovascular revascularizationClinical outcomesTissue lossPrimary patencyLimb ischemiaMean ankle-brachial indexOne-year primary patencyOne-year survival rateAnkle-brachial indexLimb salvage rateMulti-institutional experienceLevel IA evidenceInfrapopliteal applicationRevascularization benefitTibial revascularizationCause mortalityFoot infectionsInfrapopliteal lesionsArterial atherosclerosisLesion recurrenceNational trends of hybrid lower extremity revascularization in the ACS-NSQIP database
Fereydooni A, Zhou B, Jorshery SD, Deng Y, Dardik A, Chaar CIO. National trends of hybrid lower extremity revascularization in the ACS-NSQIP database. Vascular 2019, 27: 653-662. PMID: 31126228, DOI: 10.1177/1708538119852019.Peer-Reviewed Original ResearchConceptsLower extremity revascularizationExtremity revascularizationPeripheral artery diseaseVascular surgeonsSurgical specialistsPerioperative outcomesArtery diseaseHybrid surgeryHybrid procedureNational Surgical Quality Improvement Project databaseSurgeons National Surgical Quality Improvement Project databaseDisease codes -9Non-vascular surgeonsCurrent Procedural Terminology codesACS-NSQIP databaseProcedural Terminology codesNational trendsContemporary national trendsAnesthesiologists classificationEmergent surgeryOverall morbidityOnly patientsFemoral endarterectomyPropensity matching
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastases